UnitedHealth Group (NYSE:UNH) Director Rodger A. Lawson acquired 1,000 shares of the stock on the open market in a transaction dated Thursday, April 24th. The shares were purchased at an average price of $76.21 per share, for a total transaction of $76,210.00. Following the completion of the transaction, the director now directly owns 21,877 shares of the company’s stock, valued at approximately $1,667,246. UnitedHealth Group Inc. (NYSE:UNH) shares after opening at $76.57 moved to $77.29 on last trade day and at the end of the day closed at $75.66. Company price to sales ratio in past twelve months was calculated as 0.60 and price to cash ratio as 10.29. UnitedHealth Group Inc. (NYSE:UNH) showed a negative weekly performance of -0.16%.
Inovio Pharmaceuticals (NYSE:INO) CEO Jong Joseph Kim purchased 25,000 shares of the stock in a transaction dated Tuesday, April 15th. The stock was purchased at an average cost of $2.25 per share, for a total transaction of $56,250.00. Following the completion of the acquisition, the chief executive officer now directly owns 5,965,809 shares in the company, valued at approximately $13,423,070. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) shares fell -7.31% in last trading session and ended the day on $2.41. INO return on equity ratio is recorded as -144.40% and its return on assets is -92.70%. Inovio Pharmaceuticals Inc. (NYSEMKT:INO) yearly performance is 308.47%.
Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost purchased 36,300 shares of the stock on the open market in a transaction that occurred on Wednesday, April 23rd. The stock was purchased at an average cost of $8.17 per share, for a total transaction of $296,571.00. Following the transaction, the chief executive officer now directly owns 1,987,500 shares of the company’s stock, valued at approximately $16,237,875. Opko Health Inc. (NYSE:OPK) shares moved down -2.31% in last trading session and was closed at $8.05, while trading in range of $7.98 – $8.26. Opko Health Inc. (NYSE:OPK) year to date (YTD) performance is -4.62%.
Catalyst Pharmaceutical Partners (NASDAQ:CPRX) Director Charles O’keeffe purchased 5,000 shares of the stock on the open market in a transaction that occurred on Wednesday, April 16th. The stock was purchased at an average cost of $2.02 per share, with a total value of $10,100.00. Following the acquisition, the director now directly owns 182,126 shares of the company’s stock, valued at approximately $367,895. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) weekly performance is -2.91%. On last trading day company shares ended up $2.00. Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) distance from 50-day simple moving average (SMA50) is -7.38%. Analysts mean target price for the company is $4.69.
Leave a Reply